Home › Research › Biomarkers
Age-Related Prevalence of Abnormal Plasma p-Tau217 Across Racial Ethnic Groups in the Health and Aging Brain Study-Health Disparities
Joey Annette Contreras, Zara Najmi, Anhiti Dharmapuri, Charisse N. Winston, Cellas A. Hayes, as the HABS-HD Study Team. Neurology Open Access, 2026-08-25
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background and ObjectivesPlasma phosphorylated tau at threonine 217 (p-Tau217) has demonstrated high diagnostic accuracy for Alzheimer disease (AD), yet most validation studies have been conducted in predominantly non-Hispanic White (NHW) cohorts. Older age was associated with greater odds of abnormal p-Tau217 (odds ratio [OR] 1.08 per year, 95% CI 1.07–1.09), as was APOE ε4 carrier status (OR 3.32, 95% CI 2.65–4.17). Lower eGFR was independently associated with abnormal p-Tau217 (OR 0.97 per unit, 95% CI 0.96–0.97). After adjustment, NHB participants had lower odds of abnormal p-Tau217 than NHW participants (OR 0.61, 95% CI 0.45–0.82), while the association for Hispanic participants was attenuated (OR 0.76, 95% CI 0.56–1.03). Abnormal p-Tau217 was associated with higher odds of clinical cognitive impairment (OR 2.19, 95% CI 1.74–2.76).
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 2,798 participants. In a diverse cohort, older age and APOE ε4 carrier status were associated with higher odds of abnormal plasma p-Tau217, while Black participants had lower odds than non-Hispanic White participants after adjustment. Reported effect size: OR 3.32; OR 0.97; OR 0.61.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Contreras, J. A., Najmi, Z., Dharmapuri, A., Winston, C. N., Hayes, C. A., & as the HABS-HD Study Team. (2026). Age-Related Prevalence of Abnormal Plasma p-Tau217 Across Racial Ethnic Groups in the Health and Aging Brain Study-Health Disparities. Neurology Open Access. https://doi.org/10.1212/wn9.0000000000000145
Vancouver
Contreras JA, Najmi Z, Dharmapuri A, Winston CN, Hayes CA, as the HABS-HD Study Team. Age-Related Prevalence of Abnormal Plasma p-Tau217 Across Racial Ethnic Groups in the Health and Aging Brain Study-Health Disparities. Neurology Open Access. 2026. doi:10.1212/wn9.0000000000000145.
BibTeX
@article{contreras2026-2e7b0be9,
author = {Contreras, Joey Annette and Najmi, Zara and Dharmapuri, Anhiti and Winston, Charisse N. and Hayes, Cellas A. and {as the HABS-HD Study Team}},
title = {{Age-Related Prevalence of Abnormal Plasma p-Tau217 Across Racial Ethnic Groups in the Health and Aging Brain Study-Health Disparities}},
journal = {Neurology Open Access},
year = {2026},
doi = {10.1212/wn9.0000000000000145},
url = {https://doi.org/10.1212/wn9.0000000000000145}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Background and ObjectivesPlasma phosphorylated tau at threonine 217 (p-Tau217) has demonstrated high diagnostic accuracy for Alzheimer disease (AD), yet most validation studies have been conducted in predominantly non-Hispanic White (NHW) cohorts.
- Older age was associated with greater odds of abnormal p-Tau217 (odds ratio [OR] 1.08 per year, 95% CI 1.07–1.09), as was APOE ε4 carrier status (OR 3.32, 95% CI 2.65–4.17).
- Lower eGFR was independently associated with abnormal p-Tau217 (OR 0.97 per unit, 95% CI 0.96–0.97).
- After adjustment, NHB participants had lower odds of abnormal p-Tau217 than NHW participants (OR 0.61, 95% CI 0.45–0.82), while the association for Hispanic participants was attenuated (OR 0.76, 95% CI 0.56–1.03).
- Abnormal p-Tau217 was associated with higher odds of clinical cognitive impairment (OR 2.19, 95% CI 1.74–2.76).
Why it matters
In a diverse cohort, older age and APOE ε4 carrier status were associated with higher odds of abnormal plasma p-Tau217, while Black participants had lower odds than non-Hispanic White participants after adjustment. Abnormal p-Tau217 was associated with higher odds of clinical cognitive impairment, highlighting the need to consider race and ethnicity in biomarker interpretation.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants2,798
- Effect sizeOR 3.32; OR 0.97; OR 0.61
- Evidence strengthModerate
How this study scored 48/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 46 of the 96 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurology Open Access) |
| Journal's citation record | 0 / 4 | Neurology Open Access: journal h-index 5 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,798 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author as the HABS-HD Study Team holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 46 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 96 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.